Scientists find that prostate cancer patients with BRCA2 mutations require urgent treatment
Monday 8 April at 21:00 BST
Men who develop prostate cancer after inheriting a faulty gene need immediate surgery or radiotherapy rather than being placed under surveillance, as their disease is more aggressive than other types, a new study has found.
A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust found prostate cancers spread more quickly and were more often fatal in men who had inherited a faulty BRCA2 gene than in men without the faulty gene.
The research, funded by the Ronald and Rita McAulay Foundation and Cancer Research UK, could challenge current NHS guidelines for prostate cancer, under which BRCA2 mutation carriers are offered the same treatment options as non-carriers.
It is often difficult to tell at diagnosis whether prostate cancer will be life-threatening or not, and while treatment options for early-stage disease include surgery and radiotherapy, many men instead receive active surveillance to see if the disease starts to progress.
The new study, published today (Monday) in the Journal of the Clinical Oncology, is the largest to compare prostate cancer patients with and without BRCA mutations, in order to tell whether gene testing should help to direct management options.
Senior author Professor Ros Eeles, Professor of Oncogenetics at The Institute of Cancer Research (ICR) and Honorary Consultant in Clinical Oncology at The Royal Marsden, said: “It is clear from our study that prostate cancers linked to inheritance of the BRCA2 cancer gene are more deadly than other types. It must make sense to start offering affected men immediate surgery or radiotherapy, even for early-stage cases that would otherwise be classified as low-risk. We won’t be able to tell for certain that earlier treatment can benefit men with inherited cancer genes until we’ve tested it in a clinical trial, but the hope is that our study will ultimately save lives by directing treatment at those who most need it.’
The team from the ICR and The Royal Marsden, with collaborators across the UK, examined the medical records of 61 BRCA2-mutation carriers, 18 BRCA1-mutation carriers and 1,940 non-carriers.
They found BRCA1/2 mutation carriers were more likely to be diagnosed with advanced stage prostate cancers (37 per cent versus 28 per cent) or cancer that had already spread (18 per cent versus nine per cent) than non-carriers. Among those whose cancers had not spread out of the prostate at diagnosis, within five years more carriers than non-carriers had metastatic disease (23 per cent versus seven per cent).
Patients with BRCA2-mutations were also significantly less likely to survive the cancer, living an average of 6.5 years compared with 12.9 years for non-carriers. The team concluded that a BRCA2 test could be used in combination with other factors as a prognostic test. Men with a BRCA1 mutation also had a shorter average survival time of 10.5 years, but there was not a statistically significant difference with non-carriers.
Professor Alan Ashworth, Chief Executive of The Institute of Cancer Research, said: “The BRCA2 gene was discovered here at the ICR, and the gene tests that followed have offered families with an inherited risk of prostate or breast cancer the chance for close monitoring, earlier diagnosis and preventative management. Our knowledge of cancer genetics is now increasingly shaping the way we treat the disease, by allowing us to offer more intensive treatment, or even different drugs altogether, for people who have inherited cancer genes.”
Dr Julie Sharp, Senior Science Information Manager at Cancer Research UK, said: “This study shows that doctors need to consider treating men with prostate cancer and a faulty BRCA2 gene much sooner than they currently do, rather than waiting to see how the disease develops. We knew that men who inherit a faulty BRCA2 gene are at a greater risk of developing prostate cancer but this is the largest study to show that the faulty gene also makes the disease more likely to develop quickly and spread.”
Professor David Cunningham, Director of Clinical Research at The Royal Marsden, said: “Studies such as this are very important in helping us to determine how we personalise the treatment of prostate cancer patients at The Royal Marsden. This detailed understanding of men who have the BRCA1/2 gene mutations and the influence of these mutations on the progress of the prostatic cancer will mean that they will receive the tailored treatment they need quickly, and ultimately this will benefit our patients and patient outcomes.”
- ENDS -
For more information contact the ICR press office on 020 7153 5312 / firstname.lastname@example.org. For enquiries out of hours, please contact Richard Hoey, the ICR’s Director of Communications, on 07976 751 984.
Notes to editors
Around 40,800 men are diagnosed with prostate cancer in the UK each year and one Briton dies every hour from the disease.
BRCA1 / 2 mutations were originally identified in breast cancer patients and can increase the risk of developing breast and ovarian as well as prostate cancers. BRCA2 and BRCA1 mutations are present in 1.2 per cent and 0.44 per cent of prostate cancer cases, respectively. A man with a BRCA2 mutation has a 8.6-fold increased risk of developing prostate cancer, while a BRCA1 mutation gives a 3.4-fold increased risk.
Men with a significant family history of breast and /or ovarian cancer in addition to prostate cancer can be offered BRCA1/2 testing at diagnosis, however it is not routinely offered to all patients diagnosed with prostate cancer in the UK. The research team believe it should be offered to all under-65s with prostate cancer, based on a previous study that found one in 100 of these men carries the faulty gene, as it may help identify men who could benefit from new types of targeted treatment. This will, however, only become possible universally when the test is cheaper and quicker to run, as new genetic technologies are brought into mainstream cancer care.
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes.
Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients’ lives. Through its unique partnership with The Royal Marsden Hospital and ‘bench-to-bedside’ approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment. The Cancer Therapeutics Unit and Drug Development Unit at the ICR and The Royal Marsden were recently honoured with the 2012 American Association for Cancer Research Team Science Award for the “tremendous impact” of their preclinical and clinical studies.
As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR’s mission is to make the discoveries that defeat cancer. For more information visit www.icr.ac.uk
The Royal Marsden NHS Foundation Trust
The Royal Marsden opened its doors in 1851 as the world’s first hospital dedicated to cancer diagnosis, treatment, research and education.
Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe treating over 44,000 patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies. The Royal Marsden also provides community services in the London boroughs of Sutton and Merton and in June 2010, along with the ICR, the Trust launched a new academic partnership with Mount Vernon Cancer Centre in Middlesex.
Since 2004, the hospital’s charity, The Royal Marsden Cancer Charity, has helped raise over £50 million to build theatres, diagnostic centres, and drug development units.
Prince William became President of The Royal Marsden in 2007, following a long royal connection with the hospital.
For more information, visit www.royalmarsden.nhs.uk
Cancer Research UK
Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research
- The charity’s groundbreaking work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. This work is funded entirely by the public.
- Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.